Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications

被引:63
|
作者
Nakamura, Akinori [1 ]
Takeda, Shin'ichi [2 ]
机构
[1] Shinshu Univ, Sch Med, Dept Med Neurol & Rheumatol, Matsumoto, Nagano 3908621, Japan
[2] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Therapy, Kodaira, Tokyo 1878502, Japan
关键词
EXON-SKIPPING THERAPY; SKELETAL-MUSCLE; SYSTEMIC DELIVERY; CANINE MODEL; MDX MOUSE; EXPRESSION; GENE; MICE; DEGENERATION; RESTORATION;
D O I
10.1155/2011/184393
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Duchenne muscular dystrophy (DMD) is a devastating X-linked muscle disorder characterized by muscle wasting which is caused by mutations in the DMD gene. The DMD gene encodes the sarcolemmal protein dystrophin, and loss of dystrophin causes muscle degeneration and necrosis. Thus far, therapies for this disorder are unavailable. However, various therapeutic trials based on gene therapy, exon skipping, cell therapy, read through therapy, or pharmaceutical agents have been conducted extensively. In the development of therapy as well as elucidation of pathogenesis in DMD, appropriate animal models are needed. Various animal models of DMD have been identified, and mammalian (murine, canine, and feline) models are indispensable for the examination of the mechanisms of pathogenesis and the development of therapies. Here, we review the pathological features of DMD and therapeutic applications, especially of exon skipping using antisense oligonucleotides and gene therapies using viral vectors in murine and canine models of DMD.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy
    Abou-Samra, Michel
    Selvais, Camille M.
    Boursereau, Raphael
    Lecompte, Sophie
    Noel, Laurence
    Brichard, Sonia M.
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2020, 11 (02) : 518 - 533
  • [32] Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy
    Ogura, Yuji
    Tajrishi, Marjan M.
    Sato, Shuichi
    Hindi, Sajedah M.
    Kumar, Ashok
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2014, 2
  • [33] Therapeutic potential of adiponectin and adipoRon in Duchenne muscular dystrophy
    Lecompte, S.
    Abou-Samra, M.
    Boursereau, R.
    Noel, L.
    Brichard, S.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S261 - S261
  • [34] Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy
    Wells, Dominic J.
    JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, 2006, 27 (5-7) : 387 - 398
  • [35] Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy
    D'Ambrosio, Eleonora S.
    Mendell, Jerry R.
    NEUROTHERAPEUTICS, 2023, 20 (06) : 1669 - 1681
  • [36] Duchenne muscular dystrophy: Current state and therapeutic perspectives
    Le Guen, Y. T.
    Le Gall, T.
    Laurent, V
    D'Arbonneau, F.
    Braun, S.
    Montier, T.
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2021, 205 (05): : 509 - 518
  • [37] Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy
    Krishna, Lakshmi
    Prashant, Akila
    Kumar, Yogish H.
    Paneyala, Shasthara
    Patil, Siddaramappa J.
    Ramachandra, Shobha Chikkavaddaragudi
    Vishwanath, Prashant
    NEUROLOGY INTERNATIONAL, 2024, 16 (04): : 731 - 760
  • [38] Molecular Therapeutic Strategies Targeting Duchenne Muscular Dystrophy
    Mendell, Jerry R.
    Rodino-Klapac, Louise R.
    Malik, Vinod
    JOURNAL OF CHILD NEUROLOGY, 2010, 25 (09) : 1145 - 1148
  • [39] Potential therapeutic action of adiponectin in Duchenne muscular dystrophy
    Abou-Samra, M.
    Boursereau, R.
    Noel, L.
    Brichard, S.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S129 - S129
  • [40] THERAPEUTIC TRIAL OF ISAXONINE IN DUCHENNE MUSCULAR-DYSTROPHY
    HECKMATT, JZ
    HYDE, SA
    GABAIN, A
    DUBOWITZ, V
    MUSCLE & NERVE, 1988, 11 (08) : 836 - 847